Pages

Tuesday, November 4, 2014

Jazz Beats And Raises Views; Regeneron Misses In Q3

Sales climbed 32% to $306.6 million, about $4 million above analysts' estimates. The company lifted its full-year EPS outlook to $8.20-$8.35, with the midpoint 15 cents above the previous range.

http://ift.tt/1t9KDzI

No comments:

Post a Comment